CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
A Phase I/IIa Open Label, Non-Randomized, Multicenter Study of CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Aenocarcinoma
Sponsor: Celularity Incorporated
Terminated
for business reasons
A PHASE1/PHASE2 clinical study on Metastatic HER2 Positive Gastroesophageal Junction Cancer, this trial is terminated or withdrawn. The trial is conducted by Celularity Incorporated and has accumulated 12 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jan 2025 — Sep 2025 [monthly]
Terminated PHASE1/PHASE2
Status: Active Not Recruiting → Terminated
-
Sep 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Mar 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 7 earlier versions
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2022 — Feb 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2022 — Oct 2022 [monthly]
Recruiting PHASE1_PHASE2
-
May 2022 — Sep 2022 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2022 — May 2022 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Mar 2022 — Apr 2022 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Feb 2022 — Mar 2022 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Celularity Incorporated
For direct contact, visit the study record on ClinicalTrials.gov .